Insights about U.S. Stocks that landed in the Green-Zone during Thursday’s trade, are depicted underneath:

Universal Display Corporation (NASDAQ:OLED)’s shares picked up 6.26%, and closed at $38.87.

Universal Display Corp. (OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, declared that Rosemarie B. Greco has been named to the Corporation’s Board of Directors. Ms. Greco brings to Universal Display a wealth of experience in building and managing successful organizations, counting demonstrated success in executive leadership, director-level governance, building high value partnerships, and advancing projects from vision to execution.

Ms. Greco was the Chief Executive Officer and President of CoreStates Bank, N.A. and President of its parent corporation, CoreStates Financial Corp. In that role, Ms. Greco established the corporation as one of America’s most profitable and efficiently run banks. She was also instrumental in shaping CoreStates’ corporate philanthropy, service quality, and culture of employee empowerment and diversity. Preceding to her tenure at CoreStates, Ms. Greco served as President and CEO of Fidelity Bank, in addition to Chief Retail Officer and Director of First Fidelity Bancorporation.

In addition to her corporate experience, Ms. Greco has served in several civil and community leadership positions. She was named Executive Director in Pennsylvania Governor Edward G. Rendell’s Administration and became highly regarded for her ground-breaking work in health care. She advanced the needs of businesses and citizens as a member of several organizations within the State of Pennsylvania and the City of Philadelphia.

Universal Display Corporation (NASDAQ:OLED) is a leader in developing and delivering state-of-the-art, organic light emitting diode (OLED) technologies, materials and services to the display and lighting industries. Founded in 1994, the Corporation presently owns or has exclusive, co-exclusive or sole license rights with respect to more than 3,500 issued and pending patents worldwide. Universal Display licenses its proprietary technologies, counting its breakthrough high-efficiency UniversalPHOLED® phosphorescent OLED technology, that can enable the development of low power and eco-friendly displays and lighting.

Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS), raised 6.02%, and closed at $2.29.

Sunesis Pharmaceuticals, Inc. (SNSS), declared that it will host a conference call on Thursday, March 12, 2015 at 11:00 a.m. Eastern Time to talk about corporate updates and financial results for the fourth quarter and year ended December 31, 2014.

Sunesis is a biopharmaceutical corporation focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly practiced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK), enhanced 5.94%, and closed at $12.48, hitting new 52-week high of $12.50.

Merrimack Pharmaceuticals, Inc. (MACK), anticipates the following clinical milestones in 2015:

• Completion of submission of a New Drug Application to the FDA for MM-398 in late Q1/early Q2 2015;
• Initiation of a clinical trial of MM-398 in front-line pancreatic cancer; and
• Initiation of a clinical trial of MM-141 in front-line pancreatic cancer.

Full Year 2014 Financial Results:

Net loss for 2014 was $83.6 million, or basic and diluted net loss per share accessible to ordinary stockholders of $0.80, contrast with net loss for 2013 of $130.7 million, or basic and diluted net loss per share accessible to ordinary stockholders of $1.32. This decrease in net loss was primarily attributable to four factors:

• $55.0 million raise in partnership proceeds primarily attributable to the accelerated recognition of proceed as a result of the termination of Merrimack’s partnership with Sanofi effective December 17, 2014, combined with the recognition of $10.5 million of proceed related to Merrimack’s partnership with Baxter;
• $8.6 million of reduced research and development expense primarily associated with wind-down and read-out of data from several clinical trials;
• $9.3 million of raised general and administrative expense primarily attributable to raised infrastructure and personnel costs as we prepare for the potential commercialization of Merrimack’s product candidates and raised facility-related costs; and
• $7.3 million of raised interest expense primarily attributable to a full year of interest expense being recorded related to the convertible senior notes issued in July 2013.

Merrimack is a biopharmaceutical corporation discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients.

Skullcandy Inc (NASDAQ:SKUL), enhanced 5.93%, and closed at $11.07.

Skullcandy, Inc. (SKUL), declared financial results for the fourth quarter and year ended December 31, 2014.

Fourth quarter 2014 results as compared to same quarter in preceding year:

• Net sales: $96.8 million vs. $72.2 million (+34%)
• Gross margin: 43.3% vs. 43.5%
• Selling, general and administrative expense as a percentage of net sales: 32.1% vs. 35.9%
• Operating revenue: $10.8 million vs. $5.5 million (+97%)
• Net revenue per diluted share: $0.26 vs $0.13 (+100%)

Twelve months ended 2014 results as compared to twelve months ended 2013:

• Net sales: $247.8 million vs. $210.1 million (+18%)
• Gross margin: 44.6% vs. 44.3%
• Selling, general and administrative expense as a percentage of net sales: 39.9% vs. 46.7%
• Operating revenue (loss): $11.8 million vs. $(5.0) million
• Net revenue (loss) per diluted share: $0.27 vs $(0.11).

Skullcandy is the original lifestyle and performance audio brand inspired by the creativity and irreverence of youth culture. Skullcandy designs, markets and distributes audio and gaming headphones and other accessory related products under the Skullcandy, Astro Gaming and 2XL brands. Skullcandy was launched in 2003 and quickly became one of the world’s most distinct audio brands by bringing unique technology, color, character and performance to an otherwise monochromatic space; assisting to revolutionize the audio arena by introducing headphones, earbuds and other audio and wireless lifestyle products that possess unmistakable style and exceptional performance.